HealthQuill First-Quarter Earnings
Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular weight-loss drug Wegovy, as it announced its January to March operating profit rose 27% to Danish kroner 31.8 billion.
Drugs Health Pharma

Novo Nordisk raises sales forecast on strong demand for anti-obesity drug

HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.

Read More